- Home
- BQ vs CYCN Comparison
BQ vs CYCN Comparison
Compare BQ & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BQ
- CYCN
- Stock Information
- Founded
- BQ 2008
- CYCN 2018
- Country
- BQ China
- CYCN United States
- Employees
- BQ N/A
- CYCN N/A
- Industry
- BQ Other Specialty Stores
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- BQ Consumer Discretionary
- CYCN Health Care
- Exchange
- BQ Nasdaq
- CYCN Nasdaq
- Market Cap
- BQ 7.1M
- CYCN 8.0M
- IPO Year
- BQ 2020
- CYCN N/A
- Fundamental
- Price
- BQ $3.30
- CYCN $2.33
- Analyst Decision
- BQ
- CYCN
- Analyst Count
- BQ 0
- CYCN 0
- Target Price
- BQ N/A
- CYCN N/A
- AVG Volume (30 Days)
- BQ 39.8K
- CYCN 24.8K
- Earning Date
- BQ 10-28-2025
- CYCN 11-13-2025
- Dividend Yield
- BQ N/A
- CYCN N/A
- EPS Growth
- BQ N/A
- CYCN N/A
- EPS
- BQ N/A
- CYCN N/A
- Revenue
- BQ $64,617,102.00
- CYCN $2,174,000.00
- Revenue This Year
- BQ N/A
- CYCN N/A
- Revenue Next Year
- BQ N/A
- CYCN N/A
- P/E Ratio
- BQ N/A
- CYCN N/A
- Revenue Growth
- BQ N/A
- CYCN N/A
- 52 Week Low
- BQ $1.62
- CYCN $1.27
- 52 Week High
- BQ $9.89
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- BQ 57.55
- CYCN 45.15
- Support Level
- BQ $2.88
- CYCN $2.13
- Resistance Level
- BQ $3.86
- CYCN $2.59
- Average True Range (ATR)
- BQ 0.36
- CYCN 0.21
- MACD
- BQ 0.01
- CYCN 0.01
- Stochastic Oscillator
- BQ 52.94
- CYCN 32.79
About BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.